[Recurrent and chronic central serous chorioretinopathy. Retina thickness evaluation one month after intravitreal bevacizumab injection].

Abstract

PURPOSE:

To evaluate the efficacy of intavitreal injection of bevacizumab in patients with chronic central serous chorioretinopathy.

METHODS:

A study of 8 patients with central serous chorioretinopathy who were treated with intravitreal injection of bevacizumab. We studied the visual acuity with Snelleńs method and the foveal thickness, before and after the injection.

RESULTS:

The mean age of the patients was 50.25 years. After one month of follow-up, visual acuity before the injection was 0.431 ± 0.249 vision lines and after was 0.631 ± 0.310 vision lines (P=.017).The foveal thickness was 351.25 ± 78.492 μm and after treatment was 183.50 ± 22.640 μm (P=.012).

CONCLUSIONS:

Intravitreal bevacizumab can be an alternative treatment in patients with serous central chorioretinopathy as it leads to a better objective visual acuity and foveal thickness with optical coherence tomography.

• Authors: I Gregori-Gisbert, F Aguirre-Balsalobre, J García-Sánchez, G León-Salvatierra, E Mengual-Verdú, J R Hueso-Abancéns
• Journal: Archivos de la Sociedad Espanola de Oftalmologia (Arch Soc Esp Oftalmol) Vol. 86 Issue 12 Pg. 407-11 (Dec 2011) ISSN: 1989-7286 [Electronic] Spain
• Vernacular Title: Coriorretinopatía serosa central recidivante y crónica. Estudio del espesor retiniano al mes del tratamiento con una inyección de bevacizumab intravítreo.
• PMID: 22117740 (Publication Type: Clinical Trial, English Abstract, Journal Article)
• Copyright: 2010 Sociedad Española de Oftalmología. Published by Elsevier Espana. All rights reserved.

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal, Humanized
• Bevacizumab

Topics

• Adult
• Angiogenesis Inhibitors (administration & dosage, therapeutic use)
• Antibodies, Monoclonal, Humanized (administration & dosage, therapeutic use)
• Bevacizumab
• Central Serous Chorioretinopathy (drug therapy, pathology)
• Chronic Disease
• Female
• Humans
• Intravitreal Injections
• Macula Lutea (pathology)
• Male
• Middle Aged
• Recurrence
• Retina (pathology)
• Tomography, Optical Coherence
• Treatment Outcome
• Visual Acuity